Company Overview
Snapshot
Founded in July 2014 by Orahn Preiss-Bloom, OSSIO operates with 51–200 employees. The company has secured $90.06 million in total capital across 4 funding rounds from 7 investors. In February 2026, OSSIO secured debt financing, demonstrating continued investor confidence and strategic financial maneuvering.
Business overview
OSSIO is an orthopedic company that develops intelligent bone implant technology, offering an alternative to traditional metal implants within the orthopedic fixation market. Its core product, OSSIOfiber, is a biofriendly implant material designed to be stronger than cortical bone, integrate fully into native anatomy without adverse inflammation, and leave no permanent material behind. The company's proprietary technology allows for the manufacture of various implant designs for numerous surgical applications, utilizing existing reimbursement and surgical techniques. OSSIO serves the healthcare industry, specifically targeting surgeons, doctors, hospitals, and clinics with its medical devices and regenerative medicine solutions.
Strategic signal
In December 2024, OSSIO raised $27.6 million to accelerate its commercial engine, indicating strong demand for its bio-integrative fixation technology. This funding round, led by Questa Capital with participation from MVM Life Science Partners, signals significant market validation and a strategic push to expand the company's commercial reach and product adoption in the orthopedic fixation market.
Log in to access full profile ›Company Intelligence Q&A
- What was OSSIO's most recent funding activity?
- In February 2026, OSSIO secured debt financing from Horizon Technology Finance.
- Which investors participated in OSSIO's December 2024 funding round?
- In December 2024, OSSIO raised $27.6 million with participation from lead investor Questa Capital.
- What was a key development for OSSIO in October 2022?
- In October 2022, OSSIO closed a Series C financing round, with participation from MVM Life Science Partners and OurCrowd, to strengthen awareness for OSSIOfiber implants and accelerate new product platforms.
- What significant regulatory achievement did OSSIO announce in March 2022?
- In March 2022, OSSIO achieved its third FDA clearance in four months for its OSSIOfiber implants, enabling the company to expand patient and surgeon access to its bio-integrative orthopedic fixation technology portfolio.
- What strategic partnership did OSSIO secure in March 2022?
- In March 2022, OSSIO won a three-year GPO contract with Vizient, expanding access to its OSSIOfiber product line for thousands of U.S. hospitals and surgery centers.